Skip to main content

Boston Scientific Value Stock - Dividend - Research Selection

Boston scientific

ISIN: US1011371077 , WKN: 884113

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson\'s disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Nike, Boston Scientific, And Sysco Are Among Top 10 Large Cap Losers Last Week (March 30-April 2): Are the Others in Your Portfolio?

2026-04-05
Nike, Inc., Sysco Corporation and Boston Scientific Corporation led last week's large-cap losers as earnings, guidance and downgrades pressured stocks in a shortened trading week.

We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease

2026-04-04
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Boston Scientific Corp. stock outperforms competitors on strong trading day

2026-04-02
Boston Scientific Corp. stock outperforms competitors on strong trading day

Boston Scientific's 2026 Guidance 'Reasonable', RBC Says

2026-04-02
Boston Scientific's (BSX) 2026 guidance is "reasonable", but stock sentiment is being driven by the

JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch

2026-04-02
JNJ's MedTech unit rides cardiovascular strength and new product adoption, but China headwinds loom ahead of its Q1 earnings release.

Boston Scientific Corp. stock underperforms Wednesday when compared to competitors

2026-04-01
Boston Scientific Corp. stock underperforms Wednesday when compared to competitors

Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints

2026-04-01
Boston Scientific Corporation (NYSE:BSX) is one of the 10 Best 52-Week Low NYSE Stocks to Buy Now. On March 29, 2026, Boston Scientific Corporation (NYSE:BSX) announced that its CHAMPION-AF clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX device versus NOACs for stroke risk reduction in patients […]

Boston Scientific: From Hypergrowth To Durable Compounding

2026-04-01
Boston Scientific (BSX) is down 35% but still growing fast with strong margins—see valuation, key catalysts (WATCHMAN, EP, M&A), and risks.

Stocks making big moves yesterday: Avis Budget Group, Boston Scientific, CLEAR Secure, DNOW, and Comcast

2026-03-31
Check out the companies making headlines yesterday:

Are Boston Scientific’s (BSX) New Trial Wins Quietly Redefining Its Minimally Invasive Care Advantage?

2026-03-31
In late March 2026, Boston Scientific reported three advances: positive CHAMPION-AF and HI-PEITHO trial results for its WATCHMAN FLX and EKOS systems, and past FDA 510(k) clearance for the Asurys Fluid Management System for endoscopic urologic procedures. Together, these data and approvals highlight Boston Scientific’s efforts to broaden minimally invasive cardiovascular and urologic treatment options across stroke prevention, pulmonary embolism care, and kidney stone management. We’ll now...